Fresh challenge for Chinese investment in U.S. biopharma

The momentum of Chinese investment in the U.S. biopharma industry could be at risk as Trump administration officials made conflicting statements Monday as to whether the administration is considering restrictions on foreign investments in U.S. companies.

Trump trade adviser Peter Navarro confirmed Monday that the president will release a statement on China trade policy on Friday.

“To stop

Read the full 569 word article

User Sign In